BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 13 2021 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
and other hypersensitization-related disorders, today announced
that Roberto Bellini, BELLUS Health's President and Chief Executive
Officer, will present a corporate overview of the Company at the
Bloom Burton & Co. Healthcare Investor Conference.
Presentation Details:
Event: Bloom Burton & Co. Healthcare Investor
Conference Date/Time: Tuesday, April 20, 2021 at 2:00 p.m.
ET
A live webcast of the presentation may be accessed on the Events
& Presentations page under the Investors & Media section of
BELLUS Health's website at www.bellushealth.com. Following the
event, an archived webcast will be available on the Company’s
website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of refractory
chronic cough and other hypersensitization-related disorders. The
Company's product candidate, BLU-5937, is being developed for the
treatment of refractory chronic cough and chronic pruritus
associated with atopic dermatitis.
Refractory chronic cough is a cough lasting more than 8 weeks
despite appropriate treatment for underlying condition(s). It is
estimated that there are approximately 9 million patients in the
United States suffering from refractory chronic cough. Refractory
chronic cough is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for refractory
chronic cough and current treatment options are limited.
Chronic pruritus associated with atopic dermatitis is an
irritating sensation that leads to scratching and persists for
longer than 6 weeks in atopic dermatitis patients. It is estimated
that 5% of adults in the United States suffer from atopic
dermatitis – almost all report symptoms of pruritus with over 50%
of patients attributing chronic pruritus as their most burdensome
symptom. Despite currently available treatments targeting atopic
dermatitis, there continues to be a lack of options targeting the
burden of pruritus in patients with atopic dermatitis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210413005285/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024